Genmab

	12/6 10:21 af GeorgeBest	Potential in TV could be very underestimated if you listen to Pagano and also SGEN.
	12/6 10:14 af E L	ok. well that was a very concise summary ;-)
	12/6 10:11 af GeorgeBest	Just think the FDA has too much to do, and therefore could not finish in time
	12/6 10:10 af GeorgeBest	He was nor worried by the ofa delay
	12/6 10:09 af GeorgeBest	yes
	12/6 10:08 af E L	lol - did anyone listen to the Fireside Chat with Anthony Pagano yesterday?
	12/6 10:05 af Mcjean	nope its only brokers there fooling around these days
	12/6 10:02 af E L	10. on epco only. that is a lot. i don't think I had heard that yet? They are not fooling around...
	12/6 10:00 af E L	Jefferies also said "Together with Abbvie, Genmab is planning a major development program with about ten studies, most of which are phase 3"
	12/6 09:08 af Helge Larsen/PI-redaktør	Kursen holder sig flot her til morgen i forhold til anden pharma/biotek.
	12/6 08:35 af Peree	Jeg tror der skal købes op diverse steder idag :)
	12/6 08:34 af GeorgeBest	GENMAB A/S GMAB.CO : JP MORGAN RAISES PRICE TARGET TO DKK 1950 FROM DKK 1850 - Reuters News
	12/6 08:33 af bibob	Yes. A pretty Big raise. ;-)
	12/6 08:30 af E L	and it gives a good insight in what they value amyloidosis, they raise with 245dkk
	12/6 08:28 af E L	interesting to see Jefferies raise epco sales expectations based on Abbvies commercial strength
	12/6 08:14 af Helge Larsen/PI-redaktør	Genmab: Epcoritamab video: (link)
	12/6 08:04 af Helge Larsen/PI-redaktør	Asien kun med beherskede fald i nat.
	12/6 07:47 af Helge Larsen/PI-redaktør	(link)
	12/6 07:46 af Helge Larsen/PI-redaktør	God morgen. :-)
	12/6 07:44 af GeorgeBest	Tak LLI
	12/6 07:29 af bibob	@LLI. Linket dur ikke.
	12/6 06:57 af bibob	Aktiemarkedet er som kvinder. Man lærer aldrig at forstå dem. :-D
	12/6 06:56 af transalp	Go morgen.. :) Hvornår mon jeg lære det at have 20% kontant, de kan tjene penge, i det her skøre marked.. c') :)
	12/6 06:51 af bibob	GMAB US. -0,97 ( - 3,21 % )

	12/6 06:49 af bibob	God morgen. :-).
	11/6 21:53 af kkjoel	Oh, btw.. what excellent articles on Evaluate!
	11/6 21:51 af kkjoel	Both the BioNTech presentation and the new GEN video on epco were interesting. Hats off, EL, for all your gathering and sharing information on everything-Genmab :-)
	11/6 21:11 af E L	new video on the mechanism of action of epcoritamab (DuoBody®-CD3xCD20) (link)
	11/6 20:57 af Helge Larsen/PI-redaktør	NBI -4,10%
	11/6 19:58 af Mcjean	Nice article thx E L
	11/6 19:11 af E L	New Genmab/Abbvie tie-up rings old bells (link)
	11/6 16:59 af E L	BioNtech presentation from early June pdf (link)
	11/6 15:46 af Helge Larsen/PI-redaktør	Join Genmab at the virtual edition of EHA Annual Congress. Visit our booth to get latest information about our presentations, antibody technology platforms and product pipeline. (link)
	11/6 14:55 af GeorgeBest	Nightmare scenario, but in some years you will probably follow the presentations from at least 10 companies who have in licensed products from Genmab :-)
	11/6 14:49 af E L	lol GB , imagine they would have made 7 deals yesterday with 7 different companies for these 7 antibodies ;-)
	11/6 14:46 af OHW	så så, nævn ikke det navn, no go her på siten..
	11/6 14:44 af kkjoel	He he.. de har købt en manufacturing facility.. og de er ved at udvide den.. OG de vil bygge endnu en. De kan LIGE VOVE PÅ at lave en Lisa!
	11/6 14:41 af GeorgeBest	keep us updated
	11/6 14:40 af GeorgeBest	Its a full time job for you to keep up updated E L ;-)
	11/6 14:28 af E L	and Seattle Genetics from minute 13:50 for TV (link)
	11/6 14:10 af GeorgeBest	thanks E L
	11/6 13:57 af E L	Abbvie at GS conference from minute 29 (link)
	11/6 13:49 af kkjoel	Jeg har noteret 30 finanshusmål med snit på 1931.
	11/6 13:48 af kkjoel	Og nu osse H.C. Wainright ($40 ~ 2620 (kurs 6,55)) samt Suntrust Robinson ($39 ~ 2555).
	11/6 13:26 af GeorgeBest	Jo UBS og Citi har 2500
	11/6 13:25 af bikube	MedWatch påstår, at Guggenheims nye kursmål på 2350 er det hidtil højeste. Har vi ikke set mål på 2500?
	11/6 13:01 af GeorgeBest	GENMAB A/S GMAB.O: SUNTRUST ROBINSON RAISES TARGET PRICE TO $39 FROM $36 - Reuters News
	11/6 12:37 af E L	H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Genmab to $40 from $34 and keeps a Buy rating on the shares. The analyst views AbbVie as a "solid partner" for Genmab alongside Janssen (link)
	11/6 12:26 af E L	Genmab/Citi: Abbvie-aftale er bedre end ventet (link)
	11/6 11:54 af E L	ok